Brought to you by 
Actavis Group agrees to revised management takeover bid
25 Jun 2007
Executive Summary
Actavis Group chairman Bjorgolfur Thor Bjorgolfsson's UK investment company Novator is buying the part of the Icelandic generics firm it doesn't already own for €3.3bn ($4.5bn) in cash, paying €0.98 per each outstanding class A common share (about an 8% premium). Novator already held about 38.5% of Actavis's total class A common shares.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Actavis Group agrees to revised management takeover bid
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice